特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

耳鼻咽喉疾患治療の世界市場:2020年~2024年

Global ENT Disorder Treatment Market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 500846
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
耳鼻咽喉疾患治療の世界市場:2020年~2024年 Global ENT Disorder Treatment Market 2020-2024
出版日: 2020年01月10日 ページ情報: 英文 155 Pages
概要

世界の耳鼻咽喉疾患治療市場は、2020年から2024年にかけて2%のCAGRで推移し21億米ドル規模の市場に成長すると予測されています。アレルギー研究の進展、環境の急速な悪化やそれによる重度アレルギーなどによって当市場の成長が促進されています。

当レポートでは、世界の耳鼻咽喉疾患治療市場を調査し、市場の概要、適応症・地域別の市場規模の推移と予測、市場の成長要因および課題、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポート範囲

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模
  • 市場規模と予測

第5章 ファイブフォース分析

  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
  • 市況

第6章 顧客情勢

第7章 市場セグメンテーション:適応症別

  • 市場区分:適応症別
  • 市場比較:適応症別
  • 鼻炎
  • 副鼻腔炎
  • 中耳炎
  • 扁桃炎
  • 市場機会:適応症別

第8章 市場セグメンテーション:地域別

  • 市場区分:地域別
  • 市場比較:地域別
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会:地域別

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第11章 市場動向

  • 耳鼻咽喉科疾患治療に対する意識の高まり
  • 戦略的な合併と買収
  • アレルギー疾患に関する研究の進歩

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • ALK-AbellA AS
  • Bayer AG
  • Covis Pharma BV
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義
図表

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendor key offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Customer landscape
  • Exhibit 19: Indication - Market share 2019-2024 (%)
  • Exhibit 20: Comparison by indication
  • Exhibit 21: Rhinitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 22: Brief description of types of rhinitis
  • Exhibit 23: Rhinitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Sinusitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 25: Brief description of types of sinusitis
  • Exhibit 26: Sinusitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 27: Otitis media - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 28: Otitis media - Year-over-year growth 2020-2024 (%)
  • Exhibit 29: Tonsillitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 30: Tonsillitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 31: Market opportunity by indication
  • Exhibit 32: Market share by geography 2019-2024 (%)
  • Exhibit 33: Geographic comparison
  • Exhibit 34: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 35: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 38: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 40: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Growth of geriatric population 2009-2018 (%)
  • Exhibit 45: Overlapping symptoms of ENT disorders
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AbbVie Inc. - Vendor overview
  • Exhibit 53: AbbVie Inc. - Business segments
  • Exhibit 54: AbbVie Inc. - Organizational developments
  • Exhibit 55: AbbVie Inc. - Geographic focus
  • Exhibit 56: AbbVie Inc. - Key offerings
  • Exhibit 57: ALK-AbellA³ AS - Vendor overview
  • Exhibit 58: ALK-AbellA³ AS - Business segments
  • Exhibit 59: ALK-AbellA³ AS - Geographic focus
  • Exhibit 60: ALK-AbellA³ AS - Key offerings
  • Exhibit 61: Bayer AG - Vendor overview
  • Exhibit 62: Bayer AG - Business segments
  • Exhibit 63: Bayer AG - Organizational developments
  • Exhibit 64: Bayer AG - Geographic focus
  • Exhibit 65: Bayer AG - Segment focus
  • Exhibit 66: Bayer AG - Key offerings
  • Exhibit 67: Covis Pharma BV - Vendor overview
  • Exhibit 68: Covis Pharma BV - Business segments
  • Exhibit 69: Covis Pharma BV - Organizational developments
  • Exhibit 70: Covis Pharma BV - Key offerings
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 77: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 78: GlaxoSmithKline Plc - Business segments
  • Exhibit 79: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 80: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 81: GlaxoSmithKline Plc - Segment focus
  • Exhibit 82: GlaxoSmithKline Plc - Key offerings
  • Exhibit 83: Johnson & Johnson - Vendor overview
  • Exhibit 84: Johnson & Johnson - Business segments
  • Exhibit 85: Johnson & Johnson - Organizational developments
  • Exhibit 86: Johnson & Johnson - Geographic focus
  • Exhibit 87: Johnson & Johnson - Segment focus
  • Exhibit 88: Johnson & Johnson - Key offerings
  • Exhibit 89: Merck & Co. Inc. - Vendor overview
  • Exhibit 90: Merck & Co. Inc. - Business segments
  • Exhibit 91: Merck & Co. Inc. - Organizational developments
  • Exhibit 92: Merck & Co. Inc. - Geographic focus
  • Exhibit 93: Merck & Co. Inc. - Segment focus
  • Exhibit 94: Merck & Co. Inc. - Key offerings
  • Exhibit 95: Pfizer Inc. - Vendor overview
  • Exhibit 96: Pfizer Inc. - Business segments
  • Exhibit 97: Pfizer Inc. - Organizational developments
  • Exhibit 98: Pfizer Inc. - Geographic focus
  • Exhibit 99: Pfizer Inc. - Segment focus
  • Exhibit 100: Pfizer Inc. - Key offerings
  • Exhibit 101: Sanofi - Vendor overview
  • Exhibit 102: Sanofi - Business segments
  • Exhibit 103: Sanofi - Organizational developments
  • Exhibit 104: Sanofi - Geographic focus
  • Exhibit 105: Sanofi - Segment focus
  • Exhibit 106: Sanofi - Key offerings
  • Exhibit 107: Validation techniques employed for market sizing
  • Exhibit 108: Definition of market positioning of vendors
目次
Product Code: IRTNTR40834

Technavio has been monitoring the global ent disorder treatment market and it is poised to grow by USD 2.1 bn during 2020-2024, progressing at a CAGR of 2% during the forecast period. Our reports on global ent disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rapid environmental deterioration resulting in several allergic conditions.In addition, advances in research on allergic disorders is anticipated to boost the growth of the global ent disorder treatment market as well.

Market Segmentation

Technavio's global ent disorder treatment market is segmented as below:

Indication:

  • Rhinitis
  • Sinusitis
  • Otitis Media
  • Tonsillitis

Geographic segmentation

  • Asia
  • Europe
  • North America
  • ROW

Key Trends for global ent disorder treatment market growth

This study identifies advances in research on allergic disorders as the prime reasons driving the global ent disorder treatment market growth during the next few years.

Prominent vendors in global ent disorder treatment market

We provide a detailed analysis of around 25 vendors operating in the global ent disorder treatment market , including some of the vendors such as AbbVie Inc., ALK-Abello AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc. and Sanofi. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • Rhinitis - Market size and forecast 2019-2024
  • Sinusitis - Market size and forecast 2019-2024
  • Otitis media - Market size and forecast 2019-2024
  • Tonsillitis - Market size and forecast 2019-2024
  • Market opportunity by indication

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Growing awareness among people about ENT disorder treatment
  • Strategic mergers and acquisitions
  • Advances in research on allergic disorders

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • ALK-AbellA³ AS
  • Bayer AG
  • Covis Pharma BV
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO